

BEST AVAILABLE COPY

IN THE CLAIMS:

1. (Currently Amended) An isolated antigenic peptide ~~comprising an amino acid sequence~~ consisting of SEQ ID NO: 4 that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.

2. (Currently Amended) An isolated antigenic fusion protein comprising an ~~amino acid sequence~~ a CH3 domain of an IgE molecule consisting of SEQ ID NO: 4 that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal; and a heterologous carrier protein fused to said CH3 domain ~~that induces an anti-IgE immune response that does not cause anaphylaxis when administered to an animal.~~

Claims 3 – 6 (Canceled)

7. (Currently Amended) A pharmaceutical composition for inducing an anti-IgE immune response that does not cause anaphylaxis comprising one or more antigenic peptides ~~consisting of an amino acid sequence of amino acid residues of a CH3 domain of an IgE molecule or a fragment thereof~~ wherein said one or more antigenic peptide consists of SEQ ID NO: 4.

Claim 8. (Canceled)

9. (Currently Amended) A pharmaceutical composition for inducing an anti-IgE immune response that does not cause anaphylaxis comprising one or more antigenic ~~fusion proteins~~ peptides ~~consisting of an amino acid sequence of amino acid residues of a CH3 domain of an IgE molecule or a fragment thereof~~ wherein one or

more of said antigenic peptide consists of SEQ ID NO: 4; and a heterologous carrier protein fused to one or more of said antigenic peptide.

BEST AVAILABLE COPY

Claim 10. (Canceled)

11. (Previously Presented) The pharmaceutical composition of claim 9, wherein the heterologous carrier protein is selected from the group consisting of KLH, PhoE, rmLT, TraT, and gD from BhV-1 virus.

12. (Original) The pharmaceutical composition of claim 7 or 9, wherein the anti-IgE immune response is the production of anti-IgE antibodies which bind to soluble IgE in serum and other bodily fluids, prevent IgE from binding to its high affinity receptors on mast cells and basophils, and do not cross-link receptor-bound IgE.

13. (Original) The pharmaceutical composition of claim 7 or 9 further comprising an adjuvant.

Claims 14-40 (Canceled)

41. (Currently Amended) A pharmaceutical kit comprising one or more containers filled with ~~one or more of the ingredients of the~~ a pharmaceutical compositions of claim 7 or 9.